Expired CME Article
Reflux, Dyspepsia, and Disorders of the Foregut
Abstract
Disorders of the foregut are an increasingly common cause of symptoms in Western populations. This review summarizes recent advances in the understanding and treatment of gastroesophageal reflux disease, dyspepsia and celiac disease.
Key Points
* The majority of patients with reflux and dyspepsia can be safely treated without endoscopy, as most have functional disease.
* Functional heartburn and dyspepsia are chronic disorders with high relapse rates.
* Testing and treating for H pylori infection is the recommended initial strategy for most patients with dyspepsia.
* Celiac disease is underdiagnosed in primary care, and serology testing by IgA TTG should be considered in patients with gastrointestinal symptoms, iron deficiency anemia, nutrient deficiencies and early-onset osteoporosis.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710–717.
2. Nandurkar S, Locke GR III, Murray JA, et al. Rates of endoscopy and endoscopic findings among people with frequent symptoms of gastroesophageal reflux in the community. Am J Gastroenterol 2005;100:1459–1465.
3. Office of Population Censuses and Surveys. Morbidity statistics from general practice, fourth national study 1991–1992. London, HMSO, 1995. (Series MB5 No 3.)
4. Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract 2005;18:393–400.
5. Wong WM, Fass R. Extraesophageal and atypical manifestations of GERD. J Gastroenterol Hepatol 2004;19 (Suppl 3):S33–S43.
6. El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004;126:1692–1699.
7. Poelmans J, Feenstra L, Demedts I, et al. The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol2004;99:1419–1426.
8. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004;99:1652–1656.
9. Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982;307:1547–1552.
10. Fox M, Forgacs I. Gastro-oesophageal reflux disease. BMJ 2006;332:88–93.
11. Castell DO, Murray JA, Tutuian R, et al. Review article: the pathophysiology of gastro-oesophageal reflux disease: oesophageal manifestations. Aliment Pharmacol Ther 2004;20 (Suppl 9):14–25.
12. Tobey NA, Carson JL, Alkiek RA, et al. Dilated intercellular spaces: a morphological feature of acid reflux–damaged human esophageal epithelium. Gastroenterology 1996;111:1200–1205.
13. Bor S, Bor-Caymaz C, Tobey NA, et al. Esophageal exposure to ethanol increases risk of acid damage in rabbit esophagus. Dig Dis Sci 1999;44:290–300.
14. Orlando RC, Bryson JC, Powell DW. Effect of cigarette smoke on esophageal epithelium of the rabbit. Gastroenterology 1986;91:1536–1542.
15. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005;128:771–778.
16. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190–200.
17. Avidan B, Sonnenberg A, Schnell TG, et al. There are no reliable symptoms for erosive oesophagitis and Barrett’s oesophagus: endoscopic diagnosis is still essential. Aliment Pharmacol Ther 2002;16:735–742.
18. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825–1831.
19. Lieberman D, Fennerty MB, Morris CD, et al. Endoscopic evaluation of patients with dyspepsia: results from the national endoscopic data repository. Gastroenterology 2004;127:1067–1075.
20. Dellon ES, Shaheen NJ. Does screening for Barrett’s esophagus and adenocarcinoma of the esophagus prolong survival? J Clin Oncol 2005;23:4478–4482.
21. Sampliner RE. Should patients with GERD be screened once at least for Barrett’s epithelium? Pro: The need to screen GERD patients for Barrett’s esophagus–a greater yield than surveillance. Am J Gastroenterol 2004;99:2291–2293.
22. Lieberman DA. Medical therapy for chronic reflux esophagitis: long-term follow-up. Arch Intern Med 1987;147:1717–1720.
23. Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux? A critical review of the literature. Chest 1998;114:275–283.
24. Lee TJ, Fennerty MB, Howden CW. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004;20:1241–1251.
25. Ofman JJ, Dorn GH, Fennerty MB, et al. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:261–273.
26. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001;121:1095–1100.
27. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656–664.
28. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1729–1736.
29. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243–245.
30. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955–1960.
31. Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease–where next? Aliment Pharmacol Ther 2005;22:79–94.
32. Hungin AP, Rubin G, O’Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463–464.
33. Watson RG, Tham TC, Johnston BT, et al. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux–the ‘sensitive oesophagus’. Gut 1997;40:587–590.
34. Sonnenberg A. Review article: anti-reflux surgery and endoluminal therapies. Aliment Pharmacol Ther 2004;20 (Suppl 5):81–88.
35. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285:2331–38.
36. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol 2003;98:2390–2394.
37. Tran T, Spechler SJ, Richardson P, et al. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. Am J Gastroenterol 2005;100:1002–1008.
38. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a US community. Am J Med 2003;114:1–5.
39. Shaheen NJ. Raising the bar in studies of endoscopic anti-reflux procedures. Gastroenterology 2005;128:779–782.
40. Corley DA, Katz P, Wo JM, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003;125:668–676.
41. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756–1780.
42. Majumdar SR, Soumerai SB, Farraye FA, et al. Chronic acid-related disorders are common and underinvestigated. Am J Gastroenterol 2003;98:2409–2414.
43. Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259–1268.
44. Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165–177.
45. Camilleri M, Talley NJ. Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Motil 2004;16:135–142.
46. Bredenoord AJ, Chial HJ, Camilleri M, et al. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003;1:264–272.
47. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005:1;CD002096.
48. Talley NJ, Weaver AL, Tesmer DL, et al. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993;105:1378–1386.
49. Arents NL, Thijs JC, van Zwet AA, et al. Does the declining prevalence of Helicobacter pylori unmask patients with idiopathic peptic ulcer disease? Trends over an 8-year period. Eur J Gastroenterol Hepatol 2004;16:779–783.
50. Endoscopy in the evaluation of dyspepsia. Health and Public Policy Committee, American College of Physicians. Ann Intern Med 1985;102:266–269.
51. Goves J, Oldring JK, Kerr D, et al. First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther 1998;12:147–157.
52. Rabeneck L, Souchek J, Wristers K, et al. A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia. Am J Gastroenterol2002;97:3045–3051.
53. Duggan A, Elliott C, Logan RPH, et al. Does near patient H pylori testing in primary care reduce referral for endoscopy? Results from a randomised trial. Gastroenterology 1998;114 (Suppl 1):2615.
54. Jarbol D, Kragstrup J, Havelund T, et al. Efficacy of three strategies based on empirical antisecretory therapy and Helicobacter pylori status for management of dyspepsia in general practice.Gastroenterology 2003;124 (Suppl 1):A182.
55. Ladabaum U, Fendrick AM, Glidden D, et al. Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States. Am J Gastroenterol 2002;97:3007–3014.
56. Kjeldsen HC, Lauritzen T, Mainz J, et al. Evaluation of prompt proton pump inhibitor versus prompt endoscopy for management of people with dyspepsia: a one year randomised clinical trial in general practice. Gastroenterology 2004;126:A70.
57. Laheij RJ, Severens JL, Van de Lisdonk EH, et al. Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis. Aliment Pharmacol Ther 1998;12:1249–1256.
58. Ford AC, Qume M, Moayyedi P, et al. Helicobacter pylori ‘test and treat’ or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128:1838–1844.
59. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia.Cochrane Database Syst Rev 2003;1:CD001960.
60. Peura DA, Kovacs TO, Metz DC, et al. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004;116:740–748.
61. Goldstein JL. Challenges in managing NSAID-associated gastrointestinal tract injury. Digestion 2004;69 (Suppl 1):25–33.
62. Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644–R665.
63. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;4:CD002296.
64. Chey WD, Lukasik N, Huang B, et al. Lansoprazole effectively reduces the risk of GI symptom occurence in ulcer free patients who continue chronic NSAID use. Am J Gastroenterol 2003;98:S296.
65. Dubois RW, Melmed GY, Henning JM, et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004;19:197–208.
66. Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum 2005;53:185–197.
67. National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28–30, 2004. Gastroenterology 2005;128:S1–S9.
68. Dube C, Rostom A, Sy R, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 2005;128:S57–S67.
69. Zipser RD, Farid M, Baisch D, et al. Physician awareness of celiac disease: a need for further education. J Gen Intern Med 2005;20:644–646.
70. Koning F. Celiac disease: caught between a rock and a hard place. Gastroenterology 2005;129:1294–1301.
71. Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med 2002;346:180–188.
72. Dewar DH, Ciclitira PJ. Clinical features and diagnosis of celiac disease. Gastroenterology 2005;128:S19–S24.
73. Lo W, Sano K, Lebwohl B, et al. Changing presentation of adult celiac disease. Dig Dis Sci 2003;48:395–398.
74. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001;358:1504–1508.
75. Green PH, Rostami K, Marsh MN. Diagnosis of coeliac disease. Best Pract Res Clin Gastroenterol 2005;19:389–400.
76. Hill ID. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? Gastroenterology 2005;128:S25–S32.
77. Dieterich W, Laag E, Schopper H, et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology 1998;115:1317–1321.
78. Schuppan D, Dennis MD, Kelly CP. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management. Nutr Clin Care 2005;8:54–69.
79. Collin P, Reunala T, Pukkala E, et al. Coeliac disease–associated disorders and survival. Gut 1994;35:1215–1218.
80. Holmes GK, Prior P, Lane MR, et al. Malignancy in coeliac disease: effect of a gluten free diet. Gut 1989;30:333–338.
